Acute Pancreatitis

VDR genetic polymorphism will be measured by RFLP and correlated with viral, autoimmune markers.

Measurement of VDR genetic polymorphism

Assessment of the Different Etiological and Susceptibility Markers in Patients With Pancreatitis: Investigating IG4, Cytomegalovirus, Coxsackie- Virus, Genetic Polymorphism of Vitamin D Receptor Gene

Single nucleotide polymorphism of VDR mean difference will be measured by restriction fragment length polymorphism.

Reham I El-mahdy

Principal Investigator

Assiut University

Biweekly FOLFOX for two cycles alternating with FOLFIRI for two cycles (FOLFOX-FOLFIRI)

Metastatic Gastro-esophageal Adenocarcinoma

a biweekly regimen comprised of two cycles of FOLFOX alternating with two cycles of FOLFIRI.

FOLFOX and FOLFIRI

Allan Blair Cancer Center

Saskatoon Cancer Center

FOLFIRI Alternate With FOLFOX in Untreated Metastatic Gastric and Esophageal Adenocarcinoma

FOLFIRI Alternate With FOLFOX in Untreated Metastatic Gastric and Esophageal Adenocarcinoma. The LOGIC Study

Time from enrollment till the date of disease progression

Time from enrollment till death from any cause

change in baseline SUV of PET-CT after 4 cycles of chemotherapy

The European Organization for Research and the Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) along with the EORTC Esophago-Gastric Cancer Module (QLQ-OG25).

Shahid Ahmed

University of Saskatchewan

Device:
Niti-S Biliary ComVi Stent is a hollow cylindrical stent fabricated by knitting first and second super-elastic shape memory alloy wires to make a net-like structure. A plurality of interlocked points allow each of the inside and outside stent bodies to contract and expand in the longitudinal direction and to apply a force against the longitudinal contraction. A hollow polytetrafluoroethylene (PTFE) membrane tube is closely fitted between the inside and outside stent bodies, with each of overlapped ends of the PTFE membrane tube and the inside and outside stent bodies integrated into a single structure.

Device:
The Niti-S Stent (D-type) maintains a desired bent shape corresponding to the specific target lesion. It is comprised of a hollow cylindrical stent body fabricated by knitting first and second super-elastic shape memory alloy wires to make a net-like structure with a plurality of interlocked points capable of allowing the stent body to contract and expand in the longitudinal direction and to apply a force against the longitudinal contraction of the stent body.
The wires are made of a shape memory alloy through a process of shaping the alloy then heat-treating the wires to allow restoration of the original shape at a predetermined temperature.

Biliary Cancer

Endoscopic placement of biliary fully covered metal stents

Niti-S Biliary ComVi Stent

Endoscopic placement of biliary uncovered metal stent

Niti-S stent (D type)

General Hospital sanremo

Covered Versus Uncovered SEMS for Palliation of Malignant Biliary Strictures.

Covered Versus Uncovered Self-conformable Metal Stent for Palliation of Primary Malignant Extra-hepatic Biliary Strictures: a Randomized Multicenter Study

The Kaplan-Meier method will be used to estimate stent patency in each group and the log-rank test will be used for an unadjusted comparison between groups. Then a Cox proportional hazard model will be constructed to compare time to stent occlusion adjusted for important potential confounders. Stent patency will be calculated in days and will represent the interval between the time of stent insertion and the time of its replacement or the death of the patient with concomitant cholangitis.

Relationships between complication rates and stent type will be examined by the chi-square or the exact Fisher tests. Logistic regression will be used to compare stent complication rates adjusted for important potential confounders.

Health-related quality of life (HRQL) will be evaluated by a paired t-test to determine the impact of stent placement (i.e. compare baseline HRQL and month 3 HRQL) by Student's t -test to compare the differences in HRQL at baseline and 3 months between study groups. Linear regression models will be constructed to assess HQRL while adjusting for factors other than stent type.

For all analyses the Statistical Package for Social Sciences software (SPSS, Inc. for Windows will be used.

Total direct costs for each study group will be compared and cost effectiveness modelled.
For all analyses the Statistical Package for Social Sciences software (SPSS, Inc. for Windows) will be used.

MASSIMO CONIO

MD, Director of Gastroenterology Department, General Hospital Sanremo, Italy

Azienda USL 1 Imperiese

Ospedali Riuniti Marche Nord, Pesaro, Italy

NOCSAE Hospital, Modena, Italy

University of Siena, Italy

Papa Giovanni XXIII Hospital

Treatment of Pancreatic Cancer with FG-3019

Pancreatic Cancer

The FG-3019 treatment will be administered over a 28-day cycle:
Dose: 35 mg/kg
Route: IV over one hour following completion of gemcitabine infusion
Schedule:
Days 1, 8, and 15
Please note that Day 8 infusion will on be completed during the first treatment cycle

pancreatic neoplasms/phosphatase

Assessment of the Different Etiological and Susceptibility Markers in Patients With Pancreatitis: Investigating IG4, Cytomegalovirus, Coxsackie- Virus, Genetic Polymorphism of Vitamin D Receptor Gene

FOLFIRI Alternate With FOLFOX in Untreated Metastatic Gastric and Esophageal Adenocarcinoma

Covered Versus Uncovered SEMS for Palliation of Malignant Biliary Strictures.

Compassionate Single Subject Use of FG-3019 (FibroGen) in Locally Advanced, Unresectable Pancreatic Cancer

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen